… OX40 receptor blockade in AD. The Promise of Inhibiting … and disease flares. Rocatinlimab (Amgen, Kyowa Kirin) is a … a diverse, treatment-experienced AD patient population failing prior topicals … improvements vs [placebo] in AD clinical signs and symptoms …

… needs in atopic dermatitis (AD) remain regarding durability of response … proinflammatory responses implicated in AD pathogenesis. Rocatinlimab (Amgen; Kyowa Kirin) is … population with moderate to severe AD. Rocatinlimab demonstrated significant improvements …

… pathogenesis of atopic dermatitis (AD) is intricately linked to … disease flares.1 Rocatinlimab (Amgen), a humanized monoclonal antibody, … modify the course of AD. The ROCKET-SHUTTLE trial … integrate rocatinlimab into the AD treatment paradigm. References Marfil …

… moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, … with moderate to severe AD. The secondary endpoints of … of Research and Development at Amgen. “These findings add to … patients with moderate to severe AD, with possible maintenance dosing …

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in …

New York, USA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight The gout market is poised for steady growth, driven by the rising prevalence of the disease, …

New York, USA, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight The recent approval of Sanofi’s WAYRILZ has shifted the dynamics of the immune …

… or an investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx … Landscape for Moderate to Severe AD. Presented at the 2025 European …

… postprandial satiety, and reducing ad libitum food intake.132–134 … Rhythm Pharmaceuticals, Gila Therapeutics, Amgen, General Mills, Regeneron, Boehringer … db24-262-OR 83. Amgen announces robust weight loss with … 7-36) amide on ad libitum energy intake in humans …

… higher proportion of adults with AD reported experiencing suicidal ideation … female sex, moderate to severe AD according to Patient-Oriented Eczema … relationships with AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics …